By Connor Hart
Autolus Therapeutics said it received Food and Drug Administration approval of its treatment of acute lymphoblastic leukemia, or ALL, an aggressive blood and bone marrow cancer, for certain patients.
The treatment, called Aucatzyl, has been granted marketing approval for the treatment of adult patients with relapsed or refractory B-cell precursor ALL, the London biopharmaceutical company said Friday.
Its approval was based on the results of a clinical study in which 42% of patients with the cancer achieved complete remission within three months.
"Based on the experience in the Felix trial Aucatzyl is highly active and can be well managed, offering an attractive risk benefit profile for B-ALL patients," said Dr. Claire Roddie, the trial's lead investigator.
Chief Executive Christian Itin said the treatment marks Autolus' first commercial product. In addition to its U.S. approval, marketing authorization applications are being reviewed by the regulators in the European Union and the United Kingdom, the company said.
Shares rise 1.3%, to $3.78, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 08, 2024 17:38 ET (22:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。